scholarly journals Congestive Heart Failure versus Inflammatory Carcinoma in Breast

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
A. Alikhassi ◽  
R. Omranipour ◽  
Z. Alikhassy
Keyword(s):  
Breast Cancer ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Breast Carcinoma ◽  
Inflammatory Breast Cancer ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Inflammatory Breast Carcinoma ◽  
Inflammatory Carcinoma ◽  
Clinical Signs And Symptoms

Inflammatory breast cancer is a rare highly malignant form of breast cancer. Clinical signs and symptoms with histologic examination usually confirm the diagnosis. There are rare reports of breast edema of congestive heart failure which were difficult to differentiate from inflammatory carcinoma. The differential becomes more difficult when congestive heart failure is associated with unilateral breast edema. We present a case of a 70-year-old woman with congestive heart failure associated with unilateral breast edema and skin thickening simulating inflammatory breast carcinoma on mammography.

scholarly journals How long before hospital admission do the symptoms of heart failure decompensation arise?

2019 ◽  
Vol 27 ◽  
Author(s):  
Maraísa Carine Born ◽  
Karina de Oliveira Azzolin ◽  
Emiliane Nogueira de Souza
Keyword(s):  
Heart Failure ◽  
Hospital Admission ◽  
Clinical Signs ◽  
Emergency Admission ◽  
Signs And Symptoms ◽  
Cross Sectional Study ◽  
Chi Square ◽  
Cross Sectional ◽  
Clinical Signs And Symptoms ◽  
Heart Failure Decompensation

ABSTRACT Objective: to identify the signs and symptoms of decompensation of heart failure (HF) and the duration of time to hospital admission. Method: this is a cross-sectional study with adult patients hospitalized for decompensated HF in a teaching hospital located in southern Brazil from July to October 2017. Data collection was performed through a structured questionnaire that included sociodemographic, clinical signs and symptoms of HF. In the data analysis, the following tests were applied: t-Student, Mann Whitney U-Test, Chi-Square Tests. Results: 94 patients, aged between 42 and 98 years old (mean of 71.2 years old) were included. The most prevalent signs and symptoms before emergency admission were dyspnea (79.8%), cough (29.8%), orthopnea (27.7%), edema (23.4%), and fatigue (22.3%). The median time from onset of signs and symptoms to arrival in the emergency room is fatigue and edema 7 days, orthopnea 5 days, cough 4 days and dyspnea 3 days. Conclusion: the set of classic signs and symptoms of decompensation of HF occurs around seven days before the emergency search and dyspnea is the worsening that leads the patient to a hospital emergency.

scholarly journals Congestive Heart Failure Mimicking Inflammatory Breast Carcinoma: A Case Report and Review of the Literature

2001 ◽  
Vol 7 (2) ◽  
pp. 117-119 ◽  
Author(s):  
Christian O. Oraedu ◽  
Parashuram Pinnapureddy ◽  
Sadir Alrawi ◽  
Anthony J. Acinapura ◽  
Ramanathan Raju
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Case Report ◽  
Breast Carcinoma ◽  
Review Of The Literature ◽  
Inflammatory Breast Carcinoma

Chronic heart failure management and remote haemodynamic monitoring

Heart ◽  
2018 ◽  
Vol 104 (23) ◽  
pp. 1910-1919 ◽  
Author(s):  
Aaron M Wolfson ◽  
Michael Fong ◽  
Luanda Grazette ◽  
Joseph E Rahman ◽  
David M Shavelle
Keyword(s):  
Heart Failure ◽  
Remote Monitoring ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Haemodynamic Monitoring ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Clinical Signs And Symptoms

Heart failure (HF) has a large societal and economic burden and is expected to increase in magnitude and complexity over the ensuing years. A number of telemonitoring strategies exploring remote monitoring and management of clinical signs and symptoms of congestion in HF have had equivocal results. Early studies of remote haemodynamic monitoring showed promise, but issues with device integrity and implantation-associated adverse events hindered progress. Nonetheless, these early studies established that haemodynamic congestion precedes clinical congestion by several weeks and that remote monitoring of intracardiac pressures may be a viable and practical management strategy. Recently, the safety and efficacy of remote pulmonary artery pressure-guided HF management was established in a prospective, single-blind trial where randomisation to active pressure-guided HF management reduced future HF hospitalisations. Subsequent commercial use studies reinforced the utility of this technology and post hoc analyses suggest that tight haemodynamic management of patients with HF may be an additional pillar of therapy alongside established guideline-directed medical and device therapy. Currently, there is active exploration into utilisation of this technology and management paradigm for the timing of implantation of durable left ventricular assist devices (LVAD) and even optimisation of LVAD therapy. Several ongoing clinical trials will help clarify the extent and utility of this strategy along the spectrum of patient with HF from individuals with chronic, stable HF to those with more advanced disease requiring heart replacement therapy.

Patient monitoring in heart failure

ESC CardioMed ◽  
2018 ◽  
pp. 1902-1905
Author(s):  
Dirk J. van Veldhuisen ◽  
Adriaan A. Voors
Keyword(s):  
Heart Failure ◽  
Patient Monitoring ◽  
Controlled Trial ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Clinical Problem ◽  
Cardiac Resynchronization ◽  
Haemodynamic Instability ◽  
Cardiac Implantable Electronic Devices ◽  
Clinical Signs And Symptoms

Heart failure decompensation and hospital admission is a significant clinical problem. Close counselling and monitoring of patients seems attractive, to avoid clinical and haemodynamic instability. However, patient monitoring based on clinical signs and symptoms has not led to overwhelmingly positive results. The reasons for these disappointing results are unclear, but include not optimally defined protocols, and (too) easy access to healthcare providers in the intervention arm, leading to unnecessary hospitalizations, thereby making it difficult to prove benefit in a randomized controlled trial. Telemonitoring of intracardiac pressures (by stand-alone devices), in particular measurement of pulmonary artery pressure, has shown more promising results, although these data primarily come from one trial. The value of telemonitoring using cardiac implantable electronic devices (implantable cardioverter defibrillator and/or cardiac resynchronization therapy) is still unclear, but studies examining the value of intrathoracic impedance monitoring have shown disappointing results. Currently ongoing studies in all these fields will help to further define the place of telemonitoring in heart failure. Nevertheless, patient (tele)monitoring has definitely gained a place in the management of heart failure patients, and more data are needed to further establish the value and limitations of the various programmes, modalities, and components.

Role of Clinical Pharmacist in a Heart Failure Clinic

2005 ◽  
Vol 40 (10) ◽  
pp. 890-896 ◽  
Author(s):  
Devada Singh-Franco ◽  
Leanne Li ◽  
Stan Hannah ◽  
Morton Diamond
Keyword(s):  
Heart Failure ◽  
Clinical Pharmacist ◽  
Hospital Admissions ◽  
Care Service ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Medical Insurance ◽  
Post Intervention ◽  
Clinical Signs And Symptoms ◽  
The Impact

Purpose To determine if the inclusion of a clinical pharmacist (CP) in a heart failure (HF) multidisciplinary team could lead to a reduction in the number of hospital admissions and additionally decrease the clinical signs and symptoms of HF patients with either Medicaid or no medical insurance. Methods Longitudinal study to determine the impact of a pharmaceutical-care service program to HF patients by comparing the 9-month period before (pre-intervention) and the 9-month period after (post-intervention) implementation of the program. The intervention of the CP was directed in two complementary functions. The first was direct patient contact and the second was to provide drug information to the medical clinicians. Results Twenty-nine outpatients completed the study. Over 9 months, the CP made a total of 216 interventions and had three in-person, follow-up contacts and three telephone contacts per patient. At post-intervention, there was a statistically significant reduction in the total number of hospitalizations (50 vs 23; P < 0.018) and length of stay (LOS) (263 days vs 108 days; P < 0.03). However, there was an insignificant reduction in HF hospitalizations, LOS, and total number of HF signs and symptoms. Conclusions Addition of a CP to an outpatient HF clinic can lead to fewer hospital admissions and a reduction in the LOS in patients with either Medicaid or no medical insurance.

Sign in / Sign up

Export Citation Format

Share Document